Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 3:47 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 849 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Benzodiazepine Clear all

Conditions: Colitis, Ulcerative, Crohn Disease
Interventions: Caffeine, Losartan, Omeprazole, Dextromethorphan, Midazolam, Vedolizumab; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 2
States / cities: Cypress, California • Miami, Florida

Conditions: Schizophrenia
Interventions: LY2140023, Olanzapine, Aripiprazole, Risperidone, Quetiapine; Drug
Lead sponsor: Denovo Biopharma LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 560 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 42
States / cities: Little Rock, Arkansas • Escondido, California • Garden Grove, California + 39 more

Conditions: Breakthrough Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: fosaprepitant dimeglumine, systemic chemotherapy, survey administration, quality-of-life assessment; Drug · Other · Procedure
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years to 120 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Smoking Cessation, Tobacco Use Disorder
Interventions: EMB-01; Drug
Lead sponsor: Rose Research Center, LLC; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Raleigh, North Carolina

Conditions: Healthy
Interventions: olanzapine, iloperidone, Placebo; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 35 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Hepatitis C, Chronic
Interventions: midazolam, BI 201335, tenofovir, caffeine, tolbutamide, pegylated interferon, BI 207127, ribavirin; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 5
States / cities: La Mesa, California • Rockville, Maryland • Marlton, New Jersey + 2 more

Conditions: Bipolar Disorder
Interventions: lithium carbonate, Depakote-ER, risperidone, olanzapine, paroxetine, bupropion, lamotrigine, venlafaxine, tranylcypromine, mirtazapine; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 60 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania

Conditions: Sedation, Endoscopy
Interventions: Diphenhydramine, Midazolam; Drug
Lead sponsor: VA Connecticut Healthcare System; Federal
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Healthy, Pharmacokinetics of ASP015K and Midazolam
Interventions: ASP015K, Midazolam; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Pain
Interventions: Hydrocodone/acetaminophen, Placebo, Ibuprofen, Lorazepam, Lidocaine; Drug
Lead sponsor: Elizabeth Micks; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 2
States / cities: Portland, Oregon

Conditions: Malignant Melanoma, Carcinoma, Non-Small-Cell Lung, Brain Neoplasms, Primary, Brain Neoplasms, Malignant Neoplasms
Interventions: PF-07284890, Binimetinib, Midazolam; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 16 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 39
States / cities: Duarte, California • San Francisco, California • Orlando, Florida + 23 more

Conditions: Cancer, Fatigue, Ketamine
Interventions: Ketamine, Placebo (saline), Midazolam, Midazolam(placebo); Drug
Lead sponsor: National Institute of Nursing Research (NINR); NIH
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Tobacco Smoking
Interventions: Ketamine, Midazolam, Dexmedetomidine, Saline; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 21 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Vesicoureteral Reflux
Interventions: midazolam, placebo; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 2 Years to 6 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Driving Behavior
Interventions: Xanax 1Mg Tablet, Norco 10Mg-325Mg Tablet, Placebo Oral Tablet; Drug
Lead sponsor: Timothy L. Brown; Other
Eligibility: 18 Years to 40 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Healthy
Interventions: 4mg fesoterodine, 8mg fesoterodine, alprazolam 1mg, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 65 Years to 85 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 2
States / cities: Overland Park, Kansas

Conditions: Healthy Volunteers, Amyotrophic Lateral Sclerosis
Interventions: [18F]PBR06; Drug
Lead sponsor: Molecular NeuroImaging; Other
Eligibility: 18 Years to 80 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Type 1 Diabetes
Interventions: Alprazolam, Placebo; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 50 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Solid Tumors
Interventions: Savolitinib, Midazolam; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Mechanical Ventilation, Critical Illness
Interventions: Dexmedetomidine, Propofol, Fentanyl, Midazolam, Physical and Occupational Therapy; Drug · Behavioral
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Psychotic Disorders, Schizophrenia, Schizophreniform Disorders, Schizoaffective Disorders
Interventions: quetiapine, olanzapine, risperidone; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 12 Years to 18 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Seizures, Epilepsies, Partial, Epilepsy, Complex Partial, Epilepsy, Generalized, Epilepsy
Interventions: Placebo, Vanquix Auto-Injector (Diazepam Injection); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 2 Years and older
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 86
States / cities: Northport, Alabama • Little Rock, Arkansas • Irvine, California + 44 more

Conditions: Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma, Soft-Tissue Sarcoma
Interventions: AL3818, Dacarbazine, AL3818 or placebo, Midazolam 2 mg for CYP3A4 phenotyping, Digoxin (0.25mg), Rosuvastatin 10 mg tablet.; Drug
Lead sponsor: Advenchen Laboratories, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2028
U.S. locations: 17
States / cities: Phoenix, Arizona • Los Angeles, California • Santa Monica, California + 14 more

Conditions: Healthy Adults
Interventions: KP-001, Metformin, Midazolam, Clarithromycin; Drug
Lead sponsor: Kaken Pharmaceutical; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Glendale, California

Search by objective public record fields.

Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study

A Long-Term, Open-Label, Study on Schizophrenia

Fosaprepitant Dimeglumine in Treating Patients With Nausea and Vomiting Caused By Chemotherapy

Efficacy and Safety of Combination EMB-001 as a Potential Smoking Cessation Treatment

Assessment and Comparison of Metabolic Changes in Non-psychotic Adults Taking Iloperidone or Olanzapine or Placebo

Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients

Treatment of Geriatric Bipolar Mood Disorders: A Pilot Study

Randomized Trial of Diphenhydramine Versus Continued Midazolam in "Difficult-to-sedate" Patients Undergoing Colonoscopy

A Study to Assess Drug Interaction of ASP015K and Midazolam

Hydrocodone For Pain Control in First Trimester Surgical Abortion

A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement

Effect of Ketamine on Fatigue Following Cancer Therapy

The Effects of Sedatives on Tobacco Use Disorder Version 2

Midazolam Effect in Children Undergoing Voiding Cystourethrogram (VCUG)

Opiates and Benzodiazepines on Driving

A Study to Assess the Cognitive Effects of Fesoterodine in Elderly Subjects

Evaluation of Microglial Activation in ALS With [18F]PBR06 (Peripheral Benzodiazepine Receptor-06) PET

Mechanisms of Hypoglycemia Associated Autonomic Dysfunction Question 2

A Study in Healthy Male Subjects to Understand How Savolitinib When Taken With Midazolam Behaves Inside the Body

Dexmedetomidine Versus Propofol in the Medical Intensive Care Unit (MICU)

A Comparative Study of New Medications for Psychosis in Adolescents

Efficacy and Safety of Diazepam in the Management of Refractory Epilepsy in Selected Patients Who Require Intermittent Medical Intervention for Acute Repetitive Seizures.

Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)

A Study to Determine the Effect of KP-001 on Metformin and Midazolam Pharmacokinetics and the Effect of Clarithromycin on KP-001 Pharmacokinetics in Healthy Adult Participants